Healthcare / Medical Care FacilitiesThailand
$0.62
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $25.7M · quality 54.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
20/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$273M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-3.3%
↓Gross Margin
30.6%
↓Debt/Equity
0.11
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-0.8%
FCF CAGR
—
FCF margin
-22.5%
FCF / Net income
0.80x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $61.9M · net income $-17.4M · FCF $-13.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $61.9M | $61.9M | $105.7M | $121.5M | $63.3M |
| Net Income | $-17.4M | $-17.4M | $22.2M | $41.0M | $10.1M |
| EBITDA | $-3.5M | $-3.5M | $41.3M | $66.0M | $14.9M |
| EPS | -0.04 | -0.04 | 0.07 | 0.09 | 0.02 |
| Gross Margin | 30.6% | 30.6% | 58.3% | 65.4% | 49.0% |
| Operating Margin | -40.9% | -40.9% | 24.8% | 45.3% | 21.1% |
| Net Margin | -28.1% | -28.1% | 21.0% | 33.7% | 15.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.11 | 0.11 | 0.11 | 0.38 | 1.49 |
| Current Ratio | 30.89 | 30.89 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-13.9M | $-13.9M | $25.7M | $61.2M | — |
| Returns | |||||
| ROE | -3.3% | -3.3% | 4.0% | 23.1% | 17.8% |
| Valuation | |||||
| P/E | — | — | 25.72 | — | — |
| EV/EBITDA | — | — | 3.00 | — | — |
| P/B | 0.52 | 0.52 | 1.02 | — | — |
| Growth & Yield | |||||
| Revenue Growth | -41.5% | -41.5% | -13.0% | 92.0% | — |
| EPS Growth | -157.1% | -157.1% | -25.7% | 307.8% | — |
| Dividend Yield | 3.1% | 3.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-25.6%
Start / end P/E
n/dx → n/dx
EPS bridge
0.07 → -0.04
Residual
-28.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.